http://formularyjournal.modernmedicine.com/formulary Formulary provides peer-reviewed clinical information and news and drug approval updates to assist pharmacy and therapeutics committee members with their drug management responsibilities. 2009-11-07T14:50:40Z http://formularyjournal.modernmedicine.com/formulary/Comparative-effectiveness-research-could-threaten-/ArticleStandard/Article/detail/637890?ref=25 The federal government?s push to control health costs through comparative effectiveness research could threaten strides in personalized medicine, in which medicines are tailored to an individual?s genetic makeup, said the National Institutes of Health chief at a recent forum sponsored by the American Association for the Advancement of Science. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637890null HTML http://formularyjournal.modernmedicine.com/formulary/Statin-drugs-may-increase-diabetes-risk/ArticleStandard/Article/detail/637911?ref=25 Cholesterol-lowering statin drugs do not reduce the risk of diabetes and might modestly elevate the chances of developing the condition, researchers found in a pooled analysis of trial data. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637911null HTML http://formularyjournal.modernmedicine.com/formulary/Long-acting-once-a-day-insulin-dose-may-be-best-fo/ArticleStandard/Article/detail/637897?ref=25 Adding insulin to standard diabetes drugs results in better blood sugar control for many with type-2 diabetes, and the dose and timing of insulin received can make a big difference, British researchers report. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637897null HTML http://formularyjournal.modernmedicine.com/formulary/Study-results-show-risk-factors-for-ulcer-developm/ArticleStandard/Article/detail/637893?ref=25 Horizon Therapeutics Inc., a privately held biopharmaceutical company, recently presented an analysis from 2 pivotal phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine, PRNewswire reports. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637893null HTML http://formularyjournal.modernmedicine.com/formulary/New-antipsychotics-lead-to-weight-gain-in-young-pa/ArticleStandard/Article/detail/637909?ref=25 Atypical antipsychotic agents lead to a marked and rapid weight gain in children and adolescents, according to researchers at Zucker Hillside Hospital in Glen Oaks, NY and the Albert Einstein College of Medicine, NY. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637909null HTML http://formularyjournal.modernmedicine.com/formulary/Three-diet-drugs-in-final-stages-of-research-and-d/ArticleStandard/Article/detail/637892?ref=25 Three prescription diet drugs are in the final stages of development. According to USA Today, the drugs' manufacturers still have to submit their new drug applications to FDA and go through a rigorous review and approval process. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637892null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Telavancin-for-injection-Vibativ-Lipoglycopeptide-/ArticleStandard/Article/detail/636925?ref=25 New molecular entity: Telavancin for injection (Vibativ) was approved on September 11, 2009, for the treatment of complicated skin and skin-structure infections (cSSSIs) 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636925null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/630977?ref=25 Agents in late-stage development for the treatment of mixed dyslipidemia, coronary heart disease, atherosclerosis, and hypertension 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/402009/630977null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approvals-October-2009/ArticleStandard/Article/detail/636928?ref=25 Generic drugs approved by FDA (through October 2009): 1% clindamycin/5% benzoyl peroxide gel, triamcinolone acetonide nasal spray, clonidine transdermal system, betamethasone acetate and betamathasone sodium phosphate injectable suspension 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636928null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-leadership-promotes-scientific-integrity-quali/ArticleStandard/Article/detail/636932?ref=25 FDA officials are taking steps to erase the charges of incompetency and ineffectiveness that have plagued the agency for several years. 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636932null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Fampridine-SR-A-potassium-channel-blocker-for-the-/ArticleStandard/Article/detail/636929?ref=25 Fampridine-SR is a sustained-release oral medication that is pending FDA approval for the symptomatic treatment of multiple sclerosis (MS). 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636929null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Guanfacine-extended-release-tablets-Intuniv-Select/ArticleStandard/Article/detail/636926?ref=25 New formulation: Guanfacine extended-release tablets (Intuniv) were approved on September 2, 2009, for the treatment of attention-deficit/hyperactivity disorder (ADHD) 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636926null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-actions-in-brief-October-2009-Sabril-Helixate-/ArticleStandard/Article/detail/636933?ref=25 Recent FDA approvals (through October 2009) related to Sabril, Helixate FS, Valcyte, Metozolv ODT, Xyzal, Zevalin, Extavia, Astepro, Zenpep, and Bepreve 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636933null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Pipeline-preview-October-2009-doxorubicin-trab/ArticleStandard/Article/detail/636930?ref=25 Recent FDA action (through October 2009) related to doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, and quinazoline495 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636930null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Specialty-pharmacys-role-in-REMS-FDAs-new-drug-saf/ArticleStandard/Article/detail/636927?ref=25 Specialty pharmacies are uniquely positioned to play a key role in the implementation of Risk Evaluation and Mitigation Strategies (REMS). 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636927/REMSSpecialty_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Morphinenaltrexone-extended-release-capsules-Embed/ArticleStandard/Article/detail/636931?ref=25 New combination: Morphine/naltrexone extended-release capsules (Embeda) were approved on August 13, 2009, for the management of moderate-to-severe pain when continuous analgesia is needed for an extended time period 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636931null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Leukotriene-inhibitors-associated-with-neuropsychi/ArticleStandard/Article/detail/626175?ref=25 In an update to an earlier communication, FDA announced that the manufacturers of the leukotriene inhibitors montelukast (Singular), zafirlukast (Accolate), zileuton (Zyflo), and zileuton extended-release (Zyflo CR) are adding information about neuropsychiatric events to product labeling. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626175null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Ticagrelor-associated-with-lower-rate-of-death-fro/ArticleStandard/Article/detail/626121?ref=25 In the Study of Platelet Inhibition and Patient Outcomes (PLATO) published in the New England Journal of Medicine, patients with acute coronary syndrome (ACS) who were treated with ticagrelor had significant reductions in the rate of death from vascular causes, myocardial infarction (MI), or stroke and no significant increase in the rate of overall major bleeding versus patients treated with clopidogrel. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626121null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-issues-early-communication-about-ongoing-safet/ArticleStandard/Article/detail/626174?ref=25 FDA is reviewing reports of liver injury in patients treated with orlistat (prescription drug, Xenical; OTC drug, Alli) for obesity management or weight loss. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626174null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Etravirine-associated-with-severe-skin-and-hyperse/ArticleStandard/Article/detail/626171?ref=25 Tibotec has issued a Dear Healthcare Professionals letter regarding an increased risk of fatality caused by toxic epidermal necrolysis and hypersensitivity reactions, sometimes accompanied by hepatic failure, in patients treated with etravirine (Intelence). 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626171null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Perioperative-fluvastatin-treatment-associated-wit/ArticleStandard/Article/detail/626135?ref=25 In the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography III (DECREASE III) trial published in the New England Journal of Medicine, patients undergoing noncardiac vascular surgery who were treated with perioperative fluvastatin demonstrated a lower incidence of myocardial ischemia than patients treated with placebo. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626135null HTML http://formularyjournal.modernmedicine.com/formulary/ModernMedicine+Now/Medication-interventions-get-a-boost-from-a-powerf/ArticleStandard/Article/detail/626170?ref=25 Pharmacists can improve patient outcomes by following 3 major functions: identification of potential and actual medication-related problems (MRPs), resolution of actual MRPs, and prevention of potential MRPs. The best way to achieve these goals is through accurate documentation, and one of the chief obstacles to this is time?or rather the lack of it. Various software programs have been developed to help pharmacists reduce time spent identifying opportunities for interventions. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626170null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Mycophenolic-acid-associated-with-increased-risk-o/ArticleStandard/Article/detail/626173?ref=25 Novartis has issued a Dear Healthcare Professional letter regarding a risk of pure red cell aplasia (PRCA) in patients treated with mycophenolic acid (Myfortic). 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626173null HTML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/623909?ref=25 Agents in late-stage development for the treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, and short bowel syndrome 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/623909null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Golimumab-A-human-anti-TNF-alpha-monoclonal-antibo/ArticleStandard/Article/detail/624220?ref=25 Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624220null XML http://formularyjournal.modernmedicine.com/formulary/Endocrinology/Saxagliptin-Onglyza-DPP-4-inhibitor-approved-for-t/ArticleStandard/Article/detail/624223?ref=25 New molecular entity: Saxagliptin (Onglyza), a DPP-4 inhibitor, was approved on July 31, 2009, for the treatment of type 2 diabetes mellitus 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624223null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approval-September-2009-Ta/ArticleStandard/Article/detail/624226?ref=25 Generic drug approved by FDA (through September 2009): tacrolimus capsules 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624226null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Global-health-concerns-generate-new-therapies-for-/ArticleStandard/Article/detail/624228?ref=25 Even before the emergence of the swine flu pandemic, biopharmaceutical companies were investing in vaccines and treatments for lethal diseases that plague much of the world. There is growing recognition that Americans and Europeans are vulnerable to infections from overseas, and that development of new medications is critical to ensuring public health. 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624228null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-September-2009-Saphris-Tracle/ArticleStandard/Article/detail/624224?ref=25 Recent FDA approvals (through September 2009) related to Saphris, Tracleer, Livalo, Tyvaso, Tekturna HCT, Onsolis, Forteo, Invega Sustenna, Colcrys, Acuvail, Lipsovir, and Kogenate FS 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624224null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bevacizumab-Avastin-Monoclonal-antibody-approved-f/ArticleStandard/Article/detail/624227?ref=25 New indication: Bevacizumab (Avastin), a monoclonal antibody, was approved on July 31, 2009, for the treatment of metastatic renal cell carcinoma in combination with interferon alfa 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624227null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/PampT-considerations-in-fashioning-a-knowledge-bas/ArticleStandard/Article/detail/624225?ref=25 The P&T committee is positioned to provide knowledge, strategies to improve treatment of patients with cardiometabolic disorders. 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624225/MetabolicSyndrome_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-September-2009/ArticleStandard/Article/detail/625018?ref=25 P&T considerations in fashioning a knowledge base, action plan for cardiometabolic disorders and weight; Focus on golimumab; Drug Watch: Agents in late-stage development for the treatment of gastrointestinal disorders 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/372009/625018null REMOTE http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-September-2009-cethromycin-pe/ArticleStandard/Article/detail/624221?ref=25 Recent FDA action (through September 2009) related to cethromycin, pegloticase, guanfacine, denosumab, apaziquone, TZP-102, and beclomethasone 17,21-dipropionate 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624221null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Sumatriptan-Sumavel-DosePro-Needle-free-injection-/ArticleStandard/Article/detail/624222?ref=25 New formulation: Sumatriptan (Sumavel DosePro) formulated as a needle-free injection was approved on July 15, 2009, for the acute treatment of migraine and cluster headaches 2009-09-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/362009/624222null XML http://formularyjournal.modernmedicine.com/formulary/Policy+News/Healthcare-reform-to-shape-drug-coverage-costs-and/ArticleStandard/Article/detail/619981?ref=25 With healthcare-reform legislation moving forward, insurers, providers, and pharmaceutical companies are keeping a sharp eye on policy proposals likely to affect coverage, costs, and benefits. Various constituencies in the healthcare community are supporting initiatives that will increase access to healthcare and make the nation's costly healthcare system more efficient and effective. 2009-08-18T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342009/619981null HTML http://formularyjournal.modernmedicine.com/formulary/Psychiatry+and+Behavioral+Health/Initiation-of-antipsychotic-therapy-associated-wit/ArticleStandard/Article/detail/619983?ref=25 Initiation of antipsychotic therapy associated with hyperglycemia in older diabetic patients 2009-08-18T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342009/619983null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Dirucotide-trials-for-secondary-progressive-MS-dis/ArticleStandard/Article/detail/620115?ref=25 Lilly and BioMS Medical reported that their investigational agent dirucotide did not meet the primary end point of delaying disease progression in patients with secondary progressive multiple sclerosis (SPMS) in the phase 3 MAESTRO-01 trial. 2009-08-18T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342009/620115null HTML http://formularyjournal.modernmedicine.com/formulary/Men%27s+Health/Alpha-blocker-use-in-men-associated-with-decreased/ArticleStandard/Article/detail/620114?ref=25 A study published in Urology demonstrated that alpha-blocker use is associated with a lower risk of sexual dysfunction in men aged >40 years. 2009-08-18T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342009/620114null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Trial-of-sildenafil-for-PAH-in-patients-with-sickl/ArticleStandard/Article/detail/620131?ref=25 The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has prematurely terminated a trial of sildenafil for the treatment of pulmonary arterial hypertension (PAH) in adult patients with sickle cell disease because of safety concerns. 2009-08-18T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342009/620131null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/New-warnings-about-malignancies-in-pediatric-patie/ArticleStandard/Article/detail/620129?ref=25 After completing an analysis of safety data for tumor necrosis factor (TNF)-blockers, FDA has stated that there is an increased risk of lymphoma and other cancers in pediatric patients who are treated with these agents. 2009-08-18T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342009/620129null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Development-of-bifeprunox-for-maintenance-treatmen/ArticleStandard/Article/detail/620116?ref=25 Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia. 2009-08-18T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/342009/620116null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approval-August-2009/ArticleStandard/Article/detail/616630?ref=25 Generic drug approved by FDA (through August 2009): ethinyl estradiol/norgestimate tablets 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616630null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/616088?ref=25 Agents in late-stage development for the treatment of osteoarthritis and acute/chronic pain 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616088null PDF http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-August-2009-trazodone-casopit/ArticleStandard/Article/detail/616631?ref=25 Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and velaglucerase alfa 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616631null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/IVIg-treatment-associated-with-a-reduced-risk-of-A/ArticleStandard/Article/detail/616634?ref=25 In a retrospective analysis published in the journal Neurology, investigators demonstrated that previous treatment with intravenous immunoglobulin (IVIg) was associated with a reduced risk of the development of Alzheimer's disease and related disorders (ADRD) in patients aged at least 65 years. 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616634null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Rivaroxaban-A-direct-factor-Xa-inhibitor-for-VTE-p/ArticleStandard/Article/detail/616632?ref=25 Rivaroxaban is a highly potent direct factor Xa inhibitor that is pending FDA approval for the indication of venous thromboembolism (VTE) prophylaxis in patients undergoing total knee replacement or total hip replacement surgery. 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616632null XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-August-2009/ArticleStandard/Article/detail/619250?ref=25 Emerging risk factors and risk markers for CV disease; Focus on rivaroxaban; Drug Watch: Agents in late-stage development for the treatment of osteoarthritis and acute/chronic pain 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/332009/619250null REMOTE http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-August-2009-Ozurdex-Cambia-Il/ArticleStandard/Article/detail/616633?ref=25 Recent FDA approvals (through August 2009) related to Ozurdex, Cambia, Ilaris, Feraheme, Plan B One-Step, Alimta, and Isentress 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616633null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Dronedarone-Multaq-Benzofuran-derivative-approved-/ArticleStandard/Article/detail/616629?ref=25 New molecular entity: Dronedarone (Multaq), a benzofuran derivative, was approved on July 1, 2009, to reduce the risk of CV hospitalization in patients with AF 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616629null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Emerging-risk-factors-and-risk-markers-for-cardiov/ArticleStandard/Article/detail/616635?ref=25 This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification. 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616635/CardiovascularDisease_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Prasugrel-Effient-Platelet-activation-and-aggregat/ArticleStandard/Article/detail/616628?ref=25 New molecular entity: Prasugrel (Effient), a platelet activation and aggregation inhibitor, was approved on July 10, 2009, to reduce the rate of thrombotic CV events in patients with ACS undergoing PCI 2009-08-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/322009/616628null XML http://formularyjournal.modernmedicine.com/formulary/Policy+News/FDA-leaders-stress-safety-transparency-in-drug-dev/ArticleStandard/Article/detail/611696?ref=25 An important component in protecting public health, according to Margaret Hamburg, new commissioner of FDA, is to ensure access to innovative, safe, and effective medical products. 2009-07-20T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/292009/611696null HTML http://formularyjournal.modernmedicine.com/formulary/Technology+News/New-IV-smart-pump-technologies-prevent-medication-/ArticleStandard/Article/detail/611706?ref=25 Leading the drive to improve medication safety is the need to develop safer systems for monitoring and delivering drugs. 2009-07-20T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/292009/611706null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Therapeutic-considerations-in-managing-multiple-my/ArticleStandard/Article/detail/608422?ref=25 This review highlights treatment guidelines, disease staging criteria, and new therapeutic approaches to MM, including an overview of supportive care and emerging pipeline agents. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608422/MultipleMyeloma_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/ADHD-medications-may-be-linked-to-sudden-unexplain/ArticleStandard/Article/detail/608425?ref=25 A matched, case-control analysis demonstrated an association between the use of stimulant medications (used to treat attention-deficit/hyperactivity disorder [ADHD]) and sudden unexplained death in children and adolescents. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608425null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Tolvaptan-Samsca-Vasopressin-receptor-antagonist-a/ArticleStandard/Article/detail/608420?ref=25 New molecular entity: Tolvaptan (Samsca), a vasopressin receptor antagonist, was approved on May 19, 2009, for the treatment of clinically significant hypervolemic and euvolemic hyponatremia 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608420null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approval-July-2009/ArticleStandard/Article/detail/608423?ref=25 Generic drug approved by FDA (through July 2009): melphalan injection 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608423null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-July-2009-Besivance-Taxus-Lib/ArticleStandard/Article/detail/608424?ref=25 Recent FDA approvals (through July 2009) related to Besivance, Taxus Liberte Atom Stent System, Risperdal Consta, Prograf, Zipsor, Sprycel, Axert, Caldolor, and Lamictal XR 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608424null XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-July-2009/ArticleStandard/Article/detail/611339?ref=25 Therapeutic considerations in managing multiple myeloma; Focus on milnacipran; Drug Watch: Agents in late-stage development for the treatment of migraine and cluster headaches 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/292009/611339null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Milnacipran-A-serotonin-and-norepinephrine-reuptak/ArticleStandard/Article/detail/608419?ref=25 Milnacipran was recently approved by FDA for the management of fibromyalgia syndrome. Clinical trials have demonstrated that this agent may be a reasonable alternative or adjunct therapy for patients with fibromyalgia syndrome who are unable to tolerate first-line tricyclic antidepressant therapy. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608419null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Zoledronic-acid-Reclast-Bisphosphonate-approved-fo/ArticleStandard/Article/detail/608417?ref=25 New indication: Zoledronic acid (Reclast), a bisphosphonate, was approved on May 29, 2009, for the prevention of osteoporosis in postmenopausal women 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608417null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-July-2009-bucindolol-botulinu/ArticleStandard/Article/detail/608418?ref=25 Recent FDA action (through July 2009) related to bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, and paclitaxel 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608418null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Tadalafil-Adcirca-Phosphodiesterase-type-5-inhibit/ArticleStandard/Article/detail/608421?ref=25 New indication: Tadalafil (Adcirca), a phosphodiesterase type 5 inhibitor, was approved on May 22, 2009, for the treatment of pulmonary arterial hypertension (WHO Group I) 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/608421null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/607468?ref=25 Agents in late-stage development for the treatment of migraine and cluster headaches 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/272009/607468null PDF http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Elevated-CRP-alone-does-not-justify-statin-treatme/ArticleStandard/Article/detail/611397?ref=25 C-reactive protein (CRP) does not add predictive value to traditional cardiovascular risk factors, and there does not appear to be a causal association between CRP and coronary heart disease (CHD), according to results of 2 studies published in the July 1, 2009, issue of the Journal of the American Medical Association. 2009-07-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/292009/611397null HTML http://formularyjournal.modernmedicine.com/formulary/Z+Marketing/Formulary-Brand-Information/ArticleStandard/Article/detail/605362?ref=25 2009-06-22T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/262009/605362null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Inconsistent-communication-within-CPOE-poses-signi/ArticleStandard/Article/detail/603329?ref=25 A prospective study published in Archives of Internal Medicine demonstrated that despite standardization of data entry within the computerized provider order entry (CPOE) system in a specific healthcare facility, inconsistent communication in orders entered into the CPOE posed a significant safety risk. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603329null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Propylthiouracil-associated-with-increased-risk-of/ArticleStandard/Article/detail/603358?ref=25 FDA has notified healthcare professionals that there is a risk of serious liver injury, including liver failure or death, with the use of propylthiouracil in both adult and pediatric patients. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603358null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+Meetings/Immunotherapy-improves-survival-in-advanced-prosta/ArticleStandard/Article/detail/603353?ref=25 Sipuleucel-T represents the "first active immunotherapy to demonstrate improvement in overall survival for advanced prostate cancer," said David Penson, MD, MPH, who announced the results of a phase 3 study known as Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT), at the American Urological Association (AUA) 2009 Annual Meeting. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603353null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Golimumab-associated-with-risk-of-serious-fungal-i/ArticleStandard/Article/detail/603354?ref=25 Centocor Ortho Biotech has issued a Dear Healthcare Professionals letter to remind healthcare providers that golimumab (Simponi), a tumor necrosis factor (TNF)-alpha blocker, is associated with a risk of serious fungal infections. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603354null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Dutasteride-reduces-prostate-cancer-incidence-in-m/ArticleStandard/Article/detail/603360?ref=25 Dutasteride reduces the risk of biopsy-detectable prostate cancer by approximately one-fourth in men at high risk for the disease without increasing the risk of high-grade cancers, said Gerald L. Andriole, Jr, MD, at the American Urological Association (AUA) 2009 Annual Meeting. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603360null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Trial-of-sunitinib-plus-paclitaxel-for-advanced-br/ArticleStandard/Article/detail/603359?ref=25 Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603359null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Acid-suppressive-medications-associated-with-incre/ArticleStandard/Article/detail/603338?ref=25 A prospective pharmacoepidemiologic cohort study published in JAMA demonstrated that hospitalized patients treated with acid-suppressive medications were 30% more likely to develop hospital-acquired pneumonia than those who were not treated with acid-suppressive medications. 2009-06-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/242009/603338null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bucindolol-A-beta-blocker-for-the-treatment-of-hea/ArticleStandard/Article/detail/601855?ref=25 Bucindolol, an investigational agent under FDA review for the treatment of HF, is a nonspecific beta-blocker with weak alpha-blocking properties that may or may not possess intrinsic sympathomimetic activity. 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601855null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/601646?ref=25 Agents in late stage development for the treatment of Alzheimer's disease and cognitive impairment 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601646null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Overview-of-depression-and-its-management-in-child/ArticleStandard/Article/detail/601858?ref=25 This review addresses the prevalence and management of major depressive disorder (MDD) in school-aged children and adolescents, including treatment guidelines and agents under investigation for this indication. 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601858/PediatricDepression_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-June-2009/ArticleStandard/Article/detail/603718?ref=25 Depression and its management in children and adolescents; Focus on bucindolol; Drug Watch: Agents in late-stage development for the treatment of Alzheimer's disease and cognitive impairment 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/252009/603718null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Certolizumab-pegol-Cimzia-Anti-TNF-alpha-mAb-appro/ArticleStandard/Article/detail/601856?ref=25 New indication: Certolizumab pegol (Cimzia), an anti-TNF-alpha mAb, was approved on May 13, 2009, for the treatment of rheumatoid arthritis 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601856null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-June-2009-lucinactant-fenreti/ArticleStandard/Article/detail/601857?ref=25 Recent FDA action (through June 2009) related to lucinactant, fenretinide, fampridine-SR, HPN-100, vitespen, and prodarsan 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601857null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Actions+in+Brief/FDA-actions-in-brief-June-2009-Avastin-Azor-Exforg/ArticleStandard/Article/detail/601859?ref=25 Recent FDA approvals (through June 2009) related to Avastin, Azor, Exforge HCT, Cycloset, ACTOplus met XR, Lamictal ODT, Dysport, and Creon 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601859null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Golimumab-Simponi-Anti-TNF-alpha-mAb-approved-for-/ArticleStandard/Article/detail/601853?ref=25 New biologic: Golimumab (Simponi), an anti-TNF-alpha mAb, was approved on April 24, 2009, for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601853null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-gains-resources-for-strengthening-product-safe/ArticleStandard/Article/detail/601852?ref=25 FDA is stepping up oversight and enforcement activity for medical products as part of its efforts to demonstrate a vigorous approach to ensuring food and drug safety. 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601852null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Iloperidone-Fanapt-Psychotropic-agent-approved-for/ArticleStandard/Article/detail/601854?ref=25 New molecular entity: Iloperidone (Fanapt), a psychotropic agent, was approved on May 6, 2009, for the acute treatment of schizophrenia 2009-06-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/232009/601854null XML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Clinical-outcomes-with-prasugrel-not-affected-by-c/ArticleStandard/Article/detail/598436?ref=25 An analysis published in Circulation demonstrated that the pharmacokinetic, pharmacodynamic, and clinical outcomes of prasugrel treatment are not affected by common functional cytochrome P450 (CYP) genetic variants, whereas clopidogrel treatment is affected by these genetic polymorphisms. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598436null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/New-warnings-added-to-erlotinib-label/ArticleStandard/Article/detail/598513?ref=25 OSI and Genentech have issued a Dear Healthcare Professional letter regarding new warnings added to the labeling for erlotinib (Tarceva). 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598513null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Serious-ADRs-associated-with-psychotropic-use-in-c/ArticleStandard/Article/detail/598340?ref=25 Prescribing psychotropic medications for attention-deficit/hyperactivity disorder (ADHD) and other disorders in children is common around the world, even though serious adverse drug reactions (ADRs) have been reported with the use of these drugs, said speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598340null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Warning-about-suicidal-thoughts-and-actions-added-/ArticleStandard/Article/detail/598451?ref=25 FDA announced that manufacturers of antiepileptic and anticonvulsant drugs must update product labeling to include a warning about an increased risk of suicidal thoughts or actions associated with these drugs. The manufacturers must also develop Medication Guides for patient use. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598451null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Boxed-warning-added-to-labeling-of-testosterone-ge/ArticleStandard/Article/detail/598514?ref=25 FDA is requiring that a boxed warning be added to the product labeling for 2 testosterone gel products (AndroGel 1%, Solvay; Testim 1%, Auxilium). This warning states that there is a risk of virilization in children and women who are inadvertently exposed to these products. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598514null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Boxed-warning-added-to-botulinum-toxin-labeling/ArticleStandard/Article/detail/598452?ref=25 FDA has notified the manufacturers of botulinum toxin type A (Botox and Botox Cosmetic, Allergan), botulinum toxin type B (Myobloc, Solstice Neurosciences), and abobotulinumtoxinA (Dysport, Medicis/Ipsen) that the product labels need strengthened warnings, as well as a boxed warning, regarding the risk of adverse events when the effects of the toxin spread beyond the injection site. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598452null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Clinical-judgment-is-best-guide-in-determining-app/ArticleStandard/Article/detail/598441?ref=25 Good clinical pharmacy judgment is still the most useful tool in evaluating the prescription needs of seniors, according to speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida, but the pharmacy professionals still reviewed various criteria and methods that can assist in evaluating senior patients, particularly those with cardiovascular disease. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598441null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Rivaroxaban-superior-to-enoxaparin-in-preventing-V/ArticleStandard/Article/detail/598333?ref=25 Results from the Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism 4 (RECORD4) trial published in Lancet demonstrated that rivaroxaban 10 mg once daily is superior to subcutaneous (SC) enoxaparin in preventing venous thromboembolism (VTE) after total knee arthroplasty. 2009-05-15T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598333null HTML http://formularyjournal.modernmedicine.com/formulary/Drug+and+Formulary+Management/2008-Top-branded-drugs-by-total-prescriptions-and-/ArticleStandard/Article/detail/598280?ref=25 2008 Top 100 branded drugs by total prescriptions and total retail dollars 2009-05-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598280null HTML http://formularyjournal.modernmedicine.com/formulary/2008-Top-branded-drugs-by-total-retail-dollars/ArticleStandard/Article/detail/598276?ref=25 2008 Top 100 branded drugs by total dollars spent 2009-05-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598276null PDF http://formularyjournal.modernmedicine.com/formulary/2008-Top-branded-drugs-by-total-prescriptions/ArticleStandard/Article/detail/598275?ref=25 Top 100 branded drugs by total prescriptions 2009-05-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/598275null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Osteoarthritis-A-review-of-treatment-options/ArticleStandard/Article/detail/596636?ref=25 Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in the United States, especially among older adults. This article reviews nonpharmacologic and pharmacologic approaches to management of OA of the knee and hip. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596636/Osteoarthritis_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/596457?ref=25 Agents in late-stage development for the treatment of cystic fibrosis. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596457null PDF http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-May-2009/ArticleStandard/Article/detail/597579?ref=25 Osteoarthritis: A review of treatment options; Focus on liraglutide; Drug Watch: Agents in late-stage development for the treatment of cystic fibrosis 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/597579/MayCoverOsteo_thumbnail.gif http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/202009/597579null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Health-help-4-u-Mobile-telephone-technologies-come/ArticleStandard/Article/detail/596629?ref=25 Because so many people nowadays seem to be using cell phones rather than computers and e-mail to stay in touch, telemedicine programs are taking note of this trend and beginning to rely more on mobile phone technology. 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596629null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approvals-May-2009/ArticleStandard/Article/detail/596634?ref=25 Generic drugs approved by FDA (through May 2009) including drospirenone and ethinyl estradiol, levalbuterol, and topiramate 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596634null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-preview-May-2009-budesonideformoterol/ArticleStandard/Article/detail/596632?ref=25 Recent FDA action (through May 2009) related to budesonide/formoterol, sertindole, quetiapine, saxagliptin, bevacizumab, dronedarone, and ofatumumab 2009-05-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/192009/596632null XML